Biohaven Pharmaceutical Holding Co Ltd Stock News

Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.

The "old" Biohaven is gone, leaving the "new" Biohaven to rise.

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN ) has entered into a global license agreement with Bristol Myers Squibb & Co (NYSE: BMY ) to develop and commercialize taldefgrobep alfa. Taldefgrobep, a Phase 3-ready anti-myostatin adnectin, is the third development asset licensed to Biohaven from Bristol Myers Squibb. The Company will initiate the taldefgrobep Phase 3 trial for Spinal Muscular Atrophy (SMA) in 2022. Bristol Myers Squibb will be eligible for regulatory approval milestone … Full story available on Benzinga.com

Biohaven Pharmaceutical (BHVN) and Pfizer (PFE) a committee of the European Medicines Agency ((EMA)) recommended the approval of 75 mg dose of rimegepant for the acute treatment…

Biohaven Pharmaceuticals (BHVN): Q4 Non-GAAP EPS of -$2.32 misses by $0.39.Revenue of $190.01M (+441.2% Y/Y) beats by $14.47M.

Coinciding with the company’s Q4 2021 results, neurology-focused biotech, Biohaven Pharmaceutical (BHVN) announced a licensing deal with Bristol Myers Squibb (BMY) and an agreement…

NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results…

Biohaven Pharmaceuticals (NYSE:BHVN) is scheduled to announce Q4 earnings results on Friday, February 25th, before market open.The consensus EPS Estimate is -$1.93 (+28.3% Y/Y) and…

Biohaven Pharmaceutical (BHVN) began enrollment in a phase 2/3 trial of Nurtec ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis ((CRS)) with or without nasal polyps

Pfizer (PFE) and Biohaven Pharmaceutical (BHVN) announced that rimegepant known as NURTEC ODT in the U.S

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN ) and Pfizer Inc (NYSE: PFE ) reported topline results from an Asia-Pacific, Phase 3 trial of rimegepant in adults for the acute treatment of migraine. The study met its co-primary endpoints of freedom from pain and freedom from most bothersome migraine-associated symptom, including either nausea, phonophobia, or photophobia at 2-hours following a single oral dose … Full story available on Benzinga.com

Global Coalition for Adaptive Research ((GCAR)) announced that Troriluzole developed by Biohaven Pharmaceutical (BHVN) would be part of its Phase 2/3 trial, designed to evaluate…